Key result
Rosiglitazone linked to ~16% higher heart failure risk versus pioglitazone in T2DM.
Why the study?
Do noninsulin blood glucose-lowering drugs like rosiglitazone and sulfonylureas increase the risk of heart failure in patients with type 2 diabetes mellitus compared to metformin or pioglitazone?
Meta-Analysis
Do noninsulin blood glucose-lowering drugs like rosiglitazone and sulfonylureas increase the risk of heart failure in patients with type 2 diabetes mellitus compared to metformin or pioglitazone?
Effect estimate: RR 1.16 (95% CI 1.05-1.28)
In patients with type 2 diabetes, the use of rosiglitazone and sulfonylureas is associated with an increased risk of heart failure compared to metformin, though confounding by indication cannot be ruled out.
No takes yet. Share an insight, caveat, or question.
May support preferring pioglitazone over rosiglitazone in T2DM to lower HF risk; leaves open causal confirmation beyond observational data.
Varas‐Lorenzo et al. (2014) conducted a meta-analysis in Type 2 diabetes mellitus. Rosiglitazone vs. Pioglitazone was evaluated on Heart failure (RR 1.16, 95% CI 1.05-1.28). Rosiglitazone use was associated with a 16% increased risk of heart failure compared with pioglitazone use in patients with type 2 diabetes mellitus (RR 1.16).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: